The 2025 ASCO Genitourinary Cancers Symposium provides expert, multidisciplinary perspectives on the latest clinical and scientific advances in the field.
Refer to Your Unique Access URL Mentioned in the e-Flyer to Access 2025 ASCO Genitourinary Cancers Symposium
Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial.
Dr Neeraj Agarwal, MD, FASCO
Huntsman Cancer Institute at the University of Utah
The Future of Biomarkers in Renal Cell Carcinoma
Dr Samra Turajlic, MD, PhD
The Francis Crick Institute
